caa a22 4500 469117028 CHVBK 20180323133127.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF00172594 doi (NATIONALLICENCE)springer-10.1007/BF00172594 Intracerebral chemotherapy in the 9L rat brain tumor model [Elektronische Daten] [Bruce Kimler, Changnian Liu, Richard Evans, Robert Morantz] Summary: We have used the 9L rat brain tumor model to search for effective chemotherapeutic approaches to the management of brain tumors. Several antineoplastic agents which have been proposed or are currently being used for human brain tumors, including 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), bleomycin, aziridinylbenzoquinone (AZQ), cis-Platinum, and acivicin, were administered intravenously (iv), intraperitoneally (ip), or intracerebrally (ic) to rats burdened with the intracranial 9L gliosarcoma. The results confirm that BCNU is the most effective systemic agent among the chemotherapeutic agents tested as indicated by its ability to significantly increase the median survival time (MST) and life span of the tumor-burdened animals. Bleomycin is an effective agent against the intracranial 9L tumor when administered ic. While neither systemic single iv dose AZQ (0.5-2.5 mg/kg) nor multiple ip treatments (0.5-1.0 mg/kg × 5, q 6 h) were effective in prolonging the survival, single is dose AZQ (5-50 μg/rat) treatment significantly increased the MST of the treated animals (P < 0.05). Systemic AZQ treatments using higher doses produced a hematological toxicity, resulting in a decrease in MST of the treated animals. Cis-Platinum, either administered ip or ic, produced only a marginal effect on survival, although acute neurologic toxicity limited the dose of cis-Patinum that could be administered ic. Acivicin, either administered ip or ic, produced no effect on the survival of treated animals. Our results suggest that local treatment with certain antineoplastic agents may be an efficient therapy in the management of brain tumors. Kluwer Academic Publishers, 1992 rat brain tumor nationallicence intracerebral chemotherapy nationallicence intratumor chemotherapy nationallicence AZQ nationallicence bleomycin nationallicence cis-Platinum nationallicence Kimler Bruce Department of Radiation Oncology, University of Kansas Medical Center, 66160, Kansas City, KS aut Liu Changnian Department of Radiation Oncology, University of Kansas Medical Center, 66160, Kansas City, KS aut Evans Richard Department of Radiation Oncology, University of Kansas Medical Center, 66160, Kansas City, KS aut Morantz Robert Brain Tumor Institute, 63150, Kansas City, MO, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 14/3(1992-11-01), 191-200 0167-594X 14:3<191 1992 14 11060 https://doi.org/10.1007/BF00172594 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172594 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kimler Bruce Department of Radiation Oncology, University of Kansas Medical Center, 66160, Kansas City, KS aut NATIONALLICENCE 700 1- Liu Changnian Department of Radiation Oncology, University of Kansas Medical Center, 66160, Kansas City, KS aut NATIONALLICENCE 700 1- Evans Richard Department of Radiation Oncology, University of Kansas Medical Center, 66160, Kansas City, KS aut NATIONALLICENCE 700 1- Morantz Robert Brain Tumor Institute, 63150, Kansas City, MO, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 14/3(1992-11-01), 191-200 0167-594X 14:3<191 1992 14 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer